开发功能性单克隆抗体对β3肾上腺素能受体

G protein-coupled受体(GPCRs),其中最常用的药物和成功的目标,是一个大家庭multi-transmembrane蛋白质和一个重要的一类受体。超过40%的所有现代药物与蛋白质组。这些细胞表面受体受到外力作用,各种各样的配体,包括小分子和可溶性蛋白质。Monoclonal antibody (mAb) therapy has major advantages over small molecule therapy in that mAbs are more selective and therefore tend to have fewer non-specic or o-target toxicity issues, while having a longer duration of action than small molecule drugs. Unfortunately, it is extremely dicult to create antibodies against GPCRs using traditional approaches, especially for clinical applications. Multispan combines its proprietary immunization technology using its patented GPCR high expression system and in-depth expertise in developing well-designed and validated GPCR functional assays to select mAb leads that perturb disease-relevant signaling pathways. In this poster, we detail the development of Beta-3 adrenergic receptor (β3-AR) mAbs. Our preliminary data showed that several mAb clones specically bound to the receptor while increasing the receptor function by acting as agonists.